Day One Biopharmaceuticals, Inc. Income Statement
DAWN / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
Day One Biopharmaceuticals, Inc. reported $158M in revenue and $107M in net loss for FY2025. Revenue increased 20.6% from FY2024 to FY2025.
Based on SEC 10-K filings.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $158.2M | $131.2M | $0 | $0 | - | - | - |
| SG&A Expense | $120.6M | $115.5M | $75.5M | $61.3M | $29.2M | $4.7M | $1.0M |
| R&D Expense | $148.1M | $227.7M | $130.5M | $85.6M | $43.6M | $9.1M | $13.9M |
| Operating Income | -$127.8M | -$217.3M | -$206.1M | -$146.9M | -$72.7M | -$13.8M | -$14.9M |
| Interest Expense | - | - | - | $4.7M | $4.0K | -$30.0K | -$2.1M |
| Income Tax | -$2.0M | $7.1M | $0 | $0 | - | - | - |
| Net Income | -$107.3M | -$95.5M | -$188.9M | -$142.2M | -$72.8M | -$40.5M | -$12.6M |
| EPS (Basic) | -$2.37 | -$2.17 | -$2.37 | -$2.17 | -$4.62 | -$7.33 | - |
| EPS (Diluted) | -$2.37 | -$2.17 | -$2.37 | -$2.17 | -$4.62 | -$7.33 | - |
| Shares Outstanding | 101.1M | 87.2M | 79.8M | 65.5M | 37.0M | 5.5M | 5.9M |
| Operating Margin | -80.8% | -165.7% | - | - | - | - | - |
| Profit Margin | -67.8% | -72.8% | - | - | - | - | - |